Cytosorbents Corp (CTSO) stock
CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$5.37+0.03 (+0.56%)
Close on Nov 12, 2026Market cap $337.47MP/E –Yield –
Cytosorbents gross margin
Gross margin is gross profit as a percentage of revenue.
Cytosorbents's gross margin for the twelve months ending Jun 30, 2026 was 71.6%. For fiscal 2025 it was 71.5%, against 69.9% the year before. The highest annual figure on record is 76.2% in fiscal 2012.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 71.5% | +1.6 |
| FY2024 | Dec 31, 2024 | 69.9% | −0.7 |
| FY2023 | Dec 31, 2023 | 70.6% | +10.9 |
| FY2022 | Dec 31, 2022 | 59.8% | −14.6 |
| FY2021 | Dec 31, 2021 | 74.4% | +1.4 |
| FY2020 | Dec 31, 2020 | 73.0% | +2.6 |
| FY2019 | Dec 31, 2019 | 70.5% | +3.8 |
| FY2018 | Dec 31, 2018 | 66.7% | +3.1 |
| FY2017 | Dec 31, 2017 | 63.6% | +5.1 |
| FY2016 | Dec 31, 2016 | 58.5% | +4.7 |
| FY2015 | Dec 31, 2015 | 53.8% | +5.6 |
| FY2014 | Dec 31, 2014 | 48.2% | +27.1 |
| FY2013 | Dec 31, 2013 | 21.1% | −55.1 |
| FY2012 | Dec 31, 2012 | 76.2% | +8.8 |
| FY2011 | Dec 31, 2011 | 67.4% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 73.2% | +2.3 |
| Q1 FY2026 | Mar 31, 2026 | 69.2% | −2.0 |
| Q4 FY2025 | Dec 31, 2025 | 73.7% | +5.3 |
| Q3 FY2025 | Sep 30, 2025 | 70.3% | +9.3 |
| Q2 FY2025 | Jun 30, 2025 | 70.9% | −2.7 |
| Q1 FY2025 | Mar 31, 2025 | 71.1% | −5.3 |
| Q4 FY2024 | Dec 31, 2024 | 68.4% | +7.1 |
| Q3 FY2024 | Sep 30, 2024 | 61.0% | −2.6 |
| Q2 FY2024 | Jun 30, 2024 | 73.5% | +9.7 |
| Q1 FY2024 | Mar 31, 2024 | 76.5% | +18.7 |
| Q4 FY2023 | Dec 31, 2023 | 61.3% | −0.0 |
| Q3 FY2023 | Sep 30, 2023 | 63.6% | +19.0 |
| Q2 FY2023 | Jun 30, 2023 | 63.9% | +5.7 |
| Q1 FY2023 | Mar 31, 2023 | 57.7% | −16.1 |
| Q4 FY2022 | Dec 31, 2022 | 61.3% | −9.7 |
| Q3 FY2022 | Sep 30, 2022 | 44.6% | −30.2 |
| Q2 FY2022 | Jun 30, 2022 | 58.2% | −19.3 |
| Q1 FY2022 | Mar 31, 2022 | 73.8% | −0.2 |
| Q4 FY2021 | Dec 31, 2021 | 71.0% | −7.8 |
| Q3 FY2021 | Sep 30, 2021 | 74.8% | +2.2 |
| Q2 FY2021 | Jun 30, 2021 | 77.5% | +10.6 |
| Q1 FY2021 | Mar 31, 2021 | 74.0% | +1.4 |
| Q4 FY2020 | Dec 31, 2020 | 78.9% | +7.1 |
| Q3 FY2020 | Sep 30, 2020 | 72.6% | +0.4 |
| Q2 FY2020 | Jun 30, 2020 | 66.8% | −3.7 |
| Q1 FY2020 | Mar 31, 2020 | 72.6% | +6.1 |
| Q4 FY2019 | Dec 31, 2019 | 71.8% | +6.1 |
| Q3 FY2019 | Sep 30, 2019 | 72.2% | +7.9 |
| Q2 FY2019 | Jun 30, 2019 | 70.6% | +1.6 |
| Q1 FY2019 | Mar 31, 2019 | 66.5% | −1.7 |
| Q4 FY2018 | Dec 31, 2018 | 65.7% | −7.0 |
| Q3 FY2018 | Sep 30, 2018 | 64.3% | +3.9 |
| Q2 FY2018 | Jun 30, 2018 | 69.0% | +10.5 |
| Q1 FY2018 | Mar 31, 2018 | 68.2% | +8.5 |
| Q4 FY2017 | Dec 31, 2017 | 72.8% | +14.8 |
| Q3 FY2017 | Sep 30, 2017 | 60.3% | +0.3 |
| Q2 FY2017 | Jun 30, 2017 | 58.4% | – |
| Q1 FY2017 | Mar 31, 2017 | 59.7% | – |
| Q4 FY2016 | Dec 31, 2016 | 57.9% | – |
| Q3 FY2016 | Sep 30, 2016 | 60.0% | – |
See a number that looks wrong?